{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:33:52Z","timestamp":1771493632380,"version":"3.50.1"},"reference-count":187,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.blre.2005.01.002","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T15:15:25Z","timestamp":1107875725000},"page":"253-273","source":"Crossref","is-referenced-by-count":17,"title":["Infections associated with purine analogs and monoclonal antibodies"],"prefix":"10.1016","volume":"19","author":[{"given":"Farhad","family":"Ravandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2005.01.002_bib1","first-page":"98","article-title":"The infectious complications of chronic lymphocytic leukemia","volume":"25","author":"Morrison","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib2","series-title":"Management of infections in oncology patients","first-page":"105","article-title":"Infections in chronic leukemias and other hematological malignancies","author":"Ravandi","year":"2003"},{"key":"10.1016\/j.blre.2005.01.002_bib3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/asheducation-2003.1.438","article-title":"Infections in patients with hematological cancer: recent developments","author":"O\u2019Brien","year":"2003","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.blre.2005.01.002_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/archinte.132.4.562","article-title":"Infections complicating multiple myeloma and chronic lymphocytic leukemia","volume":"132","author":"Twomey","year":"1973","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2005.01.002_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/10428199409056283","article-title":"Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment","volume":"13","author":"Molica","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4065\/75.10.1039","article-title":"Infection and immunity in chronic lymphocytic leukemia","volume":"75","author":"Tsiodras","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2005.01.002_bib7","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1200\/JCO.1995.13.9.2431","article-title":"Infectious and immunosuppressive complications of purine analog therapy","volume":"13","author":"Cheson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00001432-200108000-00002","article-title":"Infectious complications of purine analog therapy","volume":"14","author":"Samonis","year":"2001","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.blre.2005.01.002_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.seminoncol.2004.02.017","article-title":"Treatment of chronic lymphocytic leukemia","volume":"31","author":"Ferrajoli","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib10","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1200\/JCO.2003.09.113","article-title":"Monoclonal antibody therapy of chronic lymphocytic leukemia","volume":"21","author":"Mavromatis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00062752-200307000-00002","article-title":"Hairy cell leukemia: an update","volume":"10","author":"Goodman","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.seminoncol.2004.02.007","article-title":"Advances in follicular lymphoma","volume":"31","author":"Archuleta","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0889-8588(05)70130-1","article-title":"Waldenstrom\u2019s macroglobulinemia","volume":"13","author":"Dimopoulos","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2005.01.002_bib14","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib15","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.2003.08.100","article-title":"Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia","volume":"21","author":"Weiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib17","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V81.11.2878.2878","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent","volume":"81","author":"Keating","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib18","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib19","article-title":"Pentostatin, cyclophosphamide, and rituximab (PCR therapy): a new active regimen for previously treated patients with Chronic Lymphocytic Leukemia (CLL)","volume":"102","author":"Weiss","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib20","first-page":"4661","article-title":"Effects on human peripheral lymphocytes of in vivo administration of 9-\u03b2-d-arabinofuranosyl-2-fluoroadenine-5\u2032-monophosphate (NSC 312887), a new purine antimetabolite","volume":"44","author":"Boldt","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2005.01.002_bib21","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/0006-2952(77)90275-1","article-title":"Biologic activity of 9-\u03b2-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-\u03b2-d-arabinofuranosyladenine","volume":"26","author":"Brockman","year":"1977","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.blre.2005.01.002_bib22","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.4049\/jimmunol.131.6.2762","article-title":"Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes","volume":"131","author":"Matsumoto","year":"1983","journal-title":"J Immunol"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2005.01.002_bib23","first-page":"S75","article-title":"Adverse and beneficial immunological effects of purine nucleoside analogues","volume":"38","author":"Dighiero","year":"1996","journal-title":"Hematol Cell Ther"},{"key":"10.1016\/j.blre.2005.01.002_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/7445","article-title":"Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling","volume":"5","author":"Frank","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2005.01.002_bib25","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib26","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/bmj.2.5257.920","article-title":"Hypogammaglobulinemia in chronic lymphocytic leukemia","volume":"2","author":"Fairley","year":"1961","journal-title":"Br Med J"},{"key":"10.1016\/j.blre.2005.01.002_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4","article-title":"Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance","volume":"61","author":"Rozman","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2005.01.002_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/1097-0142(197908)44:2<483::AID-CNCR2820440217>3.0.CO;2-Z","article-title":"Clinical staging and immunological findings in chronic lymphocytic leukemia","volume":"44","author":"Foa","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2005.01.002_bib29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1600-0609.1992.tb01805.x","article-title":"Infections and serum IgG levels in patients with chronic lymphocytic leukemia","volume":"48","author":"Itala","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1445-5994.1972.tb03935.x","article-title":"Clinical correlations with immunoglobulin levels in chronic lymphatic leukaemia","volume":"2","author":"Fiddes","year":"1972","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000206895","article-title":"Relationship between immunoglobulin levels, lymphocyte subpopulations and Rai staging in patients with B-CLL","volume":"69","author":"Whelan","year":"1983","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib32","first-page":"283","article-title":"An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL","volume":"30","author":"Dighiero","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib33","series-title":"Chronic lymphocytic leukemia: scientific advances and clinical developments","first-page":"147","article-title":"Hypogammaglobulinemia and disordered immunity in CLL","author":"Dighiero","year":"1993"},{"key":"10.1016\/j.blre.2005.01.002_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/sj.leu.2401235","article-title":"Inhibition of T cell\/B cell interaction by B-CLL cells","volume":"13","author":"Kneitz","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0167-5699(92)90068-I","article-title":"CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation","volume":"13","author":"Noelle","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.blre.2005.01.002_bib36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1084\/jem.179.3.999","article-title":"Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells","volume":"179","author":"Lotz","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2005.01.002_bib37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V70.2.396.396","article-title":"High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia","volume":"70","author":"Semenzato","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib38","series-title":"Chronic lymphocytic leukemia: scientific advances and clinical developments","first-page":"147","article-title":"Pathogenesis of immunodeficiency in chronic lymphocytic leukemia","author":"Foa","year":"1993"},{"key":"10.1016\/j.blre.2005.01.002_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2249.1992.tb06965.x","article-title":"Predictors of infection in chronic lymphocytic leukaemia (CLL)","volume":"89","author":"Griffiths","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2005.01.002_bib40","first-page":"252","article-title":"Prognostic factors in chronic lymphocytic leukemia","volume":"24","author":"Rai","year":"1987","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib41","first-page":"240a","article-title":"Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia","volume":"88","author":"Morrison","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/10428199909050963","article-title":"Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia","volume":"34","author":"Aittoniemi","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/10428199409049706","article-title":"IgG subclass levels in patients with B cell chronic lymphocytic leukaemia","volume":"14","author":"Copson","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0609.1990.tb00345.x","article-title":"Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia","volume":"44","author":"Apostolopoulos","year":"1990","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib45","first-page":"494","article-title":"Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia","volume":"10","author":"Rossi","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib46","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood.V71.6.1551.1551","article-title":"Defective helper function of purified T4 cells and excessive suppressor activity of purified T8 cells in patients with B-cell chronic lymphocytic leukemia. T4 suppressor effector cells are present in certain patients","volume":"71","author":"Kunicka","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib47","first-page":"1563","article-title":"Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals","volume":"21","author":"Prieto","year":"1993","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib48","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V83.8.2198.2198","article-title":"Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype","volume":"83","author":"Dianzani","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0090-1229(83)90133-2","article-title":"T lymphocytes in B-cell chronic lymphocytic leukemia: characterization by monoclonal antibodies and correlation with Fc receptors","volume":"26","author":"Semenzato","year":"1983","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.blre.2005.01.002_bib50","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4049\/jimmunol.158.3.1482","article-title":"Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia","volume":"158","author":"Serrano","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2005.01.002_bib51","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4049\/jimmunol.129.5.2305","article-title":"Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies","volume":"129","author":"Platsoucas","year":"1982","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2005.01.002_bib52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood.V57.3.418.418","article-title":"Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation","volume":"57","author":"Kay","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib53","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.V74.2.786.786","article-title":"T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease","volume":"74","author":"Totterman","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib54","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1182\/blood.V78.6.1569.1569","article-title":"Decreased CD45RA T cells in B-cell chronic lymphatic leukemia patients: correlation with disease stage","volume":"78","author":"Peller","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib55","first-page":"331","article-title":"CD4, CD8 and NK subsets in B-CLL","volume":"30","author":"Vuillier","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1096-8652(199707)55:4<175::AID-AJH2>3.0.CO;2-P","article-title":"Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities","volume":"55","author":"Reyes","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib57","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.leu.2403258","article-title":"Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia","volume":"18","author":"Lundin","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib58","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood.V91.11.4273","article-title":"Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1\/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia","volume":"91","author":"Tinhofer","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib59","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood.V58.6.1182.1182","article-title":"Defective immunoregulatory T-cell function in chronic lymphocytic leukemia","volume":"58","author":"Han","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.1983.tb02096.x","article-title":"T-cell functional abnormality in B-chronic lymphocytic leukaemia: evidence of a defect of the T-helper subset","volume":"54","author":"Lauria","year":"1983","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0145-2126(91)90470-E","article-title":"T-lymphocyte response to cytokines in B-chronic lymphocytic leukemia","volume":"15","author":"Briggs","year":"1991","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2005.01.002_bib62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ajh.2830300203","article-title":"Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function","volume":"30","author":"Burton","year":"1989","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib63","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V86.3.1115.1115","article-title":"Role of accessory cells in cytokine production by T cells in chronic B- cell lymphocytic leukemia","volume":"86","author":"Decker","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib64","first-page":"569","article-title":"Homologous and heterologous skin transplantation in patients with lymphomatous disease","volume":"26","author":"Miller","year":"1961","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2005.01.002_bib65","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/0002-9343(61)90159-0","article-title":"Immunologic factors and resistance to infection in chronic lymphocytic leukemia","volume":"31","author":"Miller","year":"1961","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib66","first-page":"291","article-title":"Mechanisms of infection in chronic lymphocytic leukemia","volume":"24","author":"Chapel","year":"1987","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib67","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2141.1984.tb03998.x","article-title":"Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia","volume":"58","author":"Foa","year":"1984","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib68","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V76.7.1349.1349","article-title":"Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors","volume":"76","author":"Foa","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib69","first-page":"4497","article-title":"The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response","volume":"63","author":"Orsini","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2005.01.002_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.1970.tb01417.x","article-title":"Blood volume changes in splenomegaly","volume":"18","author":"Donaldson","year":"1970","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood.V6.3.195.195","article-title":"Direct splenic arterial and venous blood studies in the hypersplenic syndromes before and after epinephrine","volume":"6","author":"Wright","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.me.13.020162.001015","article-title":"Hypersplenism","volume":"13","author":"Crosby","year":"1962","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.blre.2005.01.002_bib73","series-title":"Chronic lymphoid leukemias","first-page":"485","article-title":"Supportive care in chronic lymphocytic leukemia","author":"Ravandi","year":"2000"},{"key":"10.1016\/j.blre.2005.01.002_bib74","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.1983.1.10.652","article-title":"Hairy cell leukemia: lessons learned in twenty-five years","volume":"1","author":"Golomb","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ajh.2830160410","article-title":"Infectious complications in 127 patients with hairy cell leukemia","volume":"16","author":"Golomb","year":"1984","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib76","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.V51.5.851.851","article-title":"Infections in hairy-cell leukemia","volume":"51","author":"Bouza","year":"1978","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib77","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood.V56.3.526.526","article-title":"Host defense deficiency in hairy cell leukemia and its correction by leukocyte transfusion","volume":"56","author":"Hersh","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib78","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1001\/jama.236.16.1878","article-title":"Disseminated Mycobacterium kansasii infection complicating hairy cell leukemia","volume":"236","author":"Manes","year":"1976","journal-title":"Jama"},{"key":"10.1016\/j.blre.2005.01.002_bib79","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/0002-9343(80)90259-4","article-title":"Infections of hairy cell leukemia. Clinical evidence of a pronounced defect in cell-mediated immunity","volume":"68","author":"Mackowiak","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0002-9343(86)90634-0","article-title":"Disseminated atypical mycobacterial infection in patients with hairy cell leukemia","volume":"80","author":"Bennett","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib81","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1200\/JCO.1994.12.10.2216","article-title":"Neurotoxicity of purine analogs: a review","volume":"12","author":"Cheson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib82","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.1993.tb00165.x","article-title":"Severe immunodeficiency in patients treated with fludarabine monophosphate","volume":"50","author":"Wijermans","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib83","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","article-title":"Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]","volume":"82","author":"O\u2019Brien","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib84","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oxfordjournals.annonc.a058515","article-title":"Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia","volume":"4","author":"Bergmann","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib85","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1993.11.4.679","article-title":"High complete remission rate from 2-chloro-2\u2032-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count","volume":"11","author":"Juliusson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.bloodjournal74119","article-title":"Fludarabine: a new agent with major activity against chronic lymphocytic leukemia","volume":"74","author":"Keating","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib87","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.1991.9.1.44","article-title":"Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia","volume":"9","author":"Keating","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib88","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.1992.10.1.28","article-title":"Activity of fludarabine in previously treated non-Hodgkin\u2019s low-grade lymphoma: results of an Eastern Cooperative Oncology Group study","volume":"10","author":"Hochster","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib89","first-page":"28","article-title":"Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin\u2019s lymphomas: a phase II study of the German Low-Grade Non-Hodgkin\u2019s Lymphoma Study Group","volume":"20","author":"Hiddemann","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib90","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.1996.14.2.514","article-title":"Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"14","author":"Solal-Celigny","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib91","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2005.01.002_bib92","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.1995.13.4.983","article-title":"Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Tallman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib93","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V86.5.1710.bloodjournal8651710","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin\u2019s lymphoma","volume":"86","author":"Saven","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib94","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1046\/j.1365-2141.1996.d01-1868.x","article-title":"High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group","volume":"95","author":"Morton","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib95","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1998.16.3.850","article-title":"Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin\u2019s lymphoma","volume":"16","author":"Betticher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib96","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10428199909083391","article-title":"2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia","volume":"34","author":"Robak","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib97","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.annonc.a010604","article-title":"Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia","volume":"7","author":"Juliusson","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib98","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1989.7.4.433","article-title":"Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B","volume":"7","author":"Dillman","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib99","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jnci\/82.17.1416","article-title":"Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer","volume":"82","author":"Ho","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2005.01.002_bib100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/10428199509059649","article-title":"Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas","volume":"18","author":"Fenchel","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib101","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0609.1993.tb01599.x","article-title":"Fludarabine in patients with advanced and\/or resistant B-chronic lymphocytic leukemia","volume":"51","author":"Zinzani","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib102","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/sj.leu.2401368","article-title":"2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger","volume":"13","author":"Robak","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib103","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib104","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011","volume":"19","author":"Morrison","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib105","first-page":"315a","article-title":"Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages 3 and 4 low grade malignant non-Hodgkin\u2019s: Preliminary results from a prospective randomized phase 3 clinical trial in 381 patients","volume":"92","author":"Hagenbeek","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib106","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1023\/A:1008347425795","article-title":"Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"10","author":"Coiffier","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib107","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2002.11.068","article-title":"Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin\u2019s lymphoma previously treated with an alkylating agent or alkylator-containing regimen","volume":"20","author":"Klasa","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib108","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0609.1996.tb01935.x","article-title":"Infectious complications after 2-chlorodeoxyadenosine therapy","volume":"56","author":"Van Den Neste","year":"1996","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib109","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/10428199609093445","article-title":"Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience","volume":"21","author":"Montserrat","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib111","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia","volume":"13","author":"Saven","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib112","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"Infections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"Anaissie","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2005.01.002_bib113","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830490207","article-title":"Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for P. carinii pneumonia prophylaxis","volume":"49","author":"Byrd","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2005.01.002_bib114","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial","volume":"96","author":"Robak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1521-6926(02)00089-0","article-title":"Cladribine in the treatment of hairy-cell leukaemia","volume":"16","author":"Goodman","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib116","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib117","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1521-6926(03)00002-1","article-title":"Pentostatin in the treatment of hairy-cell leukemia","volume":"16","author":"Grever","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib118","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2141.1999.01546.x","article-title":"Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine","volume":"106","author":"Dearden","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib119","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib120","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood.V83.10.2906.2906","article-title":"2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib121","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V88.6.1954.bloodjournal8861954","article-title":"Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience","volume":"88","author":"Tallman","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib122","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.leu.2400619","article-title":"Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey","volume":"11","author":"Lauria","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib123","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1997.15.3.1138","article-title":"Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up","volume":"15","author":"Hoffman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib124","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/sj.leu.2403418","article-title":"An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine","volume":"18","author":"Jehn","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1989.7.2.168","article-title":"Pentostatin in the treatment of advanced hairy cell leukemia","volume":"7","author":"Kraut","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib126","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<65::AID-CNCR9>3.0.CO;2-B","article-title":"Long term outcome of patients with hairy cell leukemia treated with pentostatin","volume":"85","author":"Ribeiro","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2005.01.002_bib127","first-page":"32","article-title":"Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study","volume":"27","author":"Johnston","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mpo.2950180307","article-title":"2\u2032-Deoxycoformycin (pentostatin) for refractory non-Hodgkin\u2019s lymphoma: a CALGB phase II study","volume":"18","author":"Duggan","year":"1990","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib129","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib130","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2005.01.002_bib131","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/1042819021000006547","article-title":"Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia","volume":"43","author":"Keating","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib132","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/cncr.0680","article-title":"Frequency and type of serious infections in fludarabine-refractory B- cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population","volume":"94","author":"Perkins","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2005.01.002_bib133","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843","article-title":"In vitro evaluation of fludarabine in combination with cyclophosphamide and\/or mitoxantrone in B-cell chronic lymphocytic leukemia","volume":"94","author":"Bellosillo","year":"1999","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2005.01.002_bib134","first-page":"S140","article-title":"Combination therapy with nucleoside analogs and alkylating agents","volume":"8","author":"Johnston","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib135","article-title":"Improved survival in patients with relapsed refractory Chronic Lymphocytic Leukemia (CLL) treated with Fludarabine, Cyclophosphamide, and Rituximab (FCR) combination","volume":"102","author":"Wierda","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib136","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/sj.leu.2400816","article-title":"Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia","volume":"11","author":"O\u2019Brien","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib137","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","article-title":"Rituximab","volume":"58","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2005.01.002_bib138","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib139","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib140","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib141","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib142","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib143","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0609.1997.tb01403.x","article-title":"Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)","volume":"58","author":"Osterborg","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib144","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib145","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","article-title":"CAMPATH-1H monoclonal antibody in therapy for previously treated low- grade non-Hodgkin\u2019s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin\u2019s Lymphoma","volume":"16","author":"Lundin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib146","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib147","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B- cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib148","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","article-title":"Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia","volume":"98","author":"O\u2019Brien","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2005.01.002_bib149","unstructured":"Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002;87:695-700, discussion 700."},{"key":"10.1016\/j.blre.2005.01.002_bib150","first-page":"205a","article-title":"A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukamia Group B (CALGB) study 19901","volume":"100","author":"Rai","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib151","first-page":"676a","article-title":"Subcutaneous alemtuzumab following fludarbine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB Study 19901","volume":"102","author":"Rai","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib152","article-title":"Alemtuzumab (Campath, MabCampath) consolidation after fludarabine phosphate and cyclophosphamide second-Line chemotherapy for progressive chronic lymphocytic leukemia","volume":"102","author":"Vitolo","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib153","first-page":"676a","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"102","author":"Wendtner","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib154","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2141.2001.03143.x","article-title":"Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia","volume":"115","author":"Hagberg","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib155","first-page":"1046","article-title":"Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia","volume":"86","author":"Lauria","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2005.01.002_bib156","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2003-01-0014","article-title":"Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia","volume":"102","author":"Nieva","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib157","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2003-02-0630","article-title":"Rituximab in relapsed or refractory hairy cell leukemia","volume":"102","author":"Thomas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib158","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3816\/CLM.2003.n.026","article-title":"Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin\u2019s lymphoma: an effective and minimally toxic regimen","volume":"4","author":"Drapkin","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib159","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib161","first-page":"603","article-title":"Results of a phase II trial of fludarabine with concomitant application of alemtuzumab in a four-weekly schedule (FluCam) in patients with relapsed CLL","volume":"23","author":"Elter","year":"2004","journal-title":"Proceedings of ASCO"},{"key":"10.1016\/j.blre.2005.01.002_bib162","first-page":"3555","article-title":"A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia","volume":"9","author":"Frankel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2005.01.002_bib163","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib164","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib165","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib166","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.V86.6.2063.bloodjournal8662063","article-title":"Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal [see comments]","volume":"86","author":"Uzun","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib167","first-page":"S38","article-title":"Prophylactic strategies to meet infectious complications in fludarabine-treated CLL","volume":"11","author":"Sudhoff","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib168","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11864-001-0037-1","article-title":"Infectious complications in chronic lymphoid malignancy","volume":"2","author":"Egerer","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.blre.2005.01.002_bib169","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CLM.2004.n.002","article-title":"Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia","volume":"4","author":"Keating","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib170","first-page":"366a","article-title":"Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed\/refractory chronic lymphocytic leukemia (CLL)","volume":"98","author":"Cao","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib171","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0002-9343(84)90344-9","article-title":"Use of intravenous immunoglobulin in chronic lymphocytic leukemia","volume":"76","author":"Besa","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2005.01.002_bib172","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib173","first-page":"224a","article-title":"Intravenous immunoglobulin reduces bacterial infections in chronic lymphocytic leukemia: a controlled, randomized clinical trial","volume":"70","author":"Bunch","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib174","doi-asserted-by":"crossref","unstructured":"Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia: intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. New Eng J Med 1988;6:902\u20137.","DOI":"10.1056\/NEJM198810063191403"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2005.01.002_bib175","first-page":"17","article-title":"Intravenous immune globulin in chronic lymphocytic leukaemia","volume":"97","author":"Gamm","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2005.01.002_bib176","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","article-title":"Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes","volume":"88","author":"Chapel","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib177","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2005.01.002_bib178","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.1994.tb01874.x","article-title":"Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin","volume":"53","author":"Jurlander","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib179","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000204315","article-title":"Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients [see comments]","volume":"91","author":"Gribabis","year":"1994","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000204095","article-title":"Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients [letter; comment]","volume":"93","author":"Bucalossi","year":"1995","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2005.01.002_bib181","first-page":"20","article-title":"Interleukin-2 is effective in reducing the fludarabine-induced CD4+ depletion","volume":"90","author":"Fenchel","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib182","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/10428199909050958","article-title":"Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study","volume":"34","author":"Dmoszynska","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib183","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/10428199809057569","article-title":"Cladribine for untreated or early low-grade non-Hodgkin\u2019s lymphoma","volume":"30","author":"Liliemark","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2005.01.002_bib184","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.leu.2402752","article-title":"A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211","volume":"17","author":"Byrd","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2005.01.002_bib185","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.V93.8.2471","article-title":"Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia","volume":"93","author":"Saven","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2005.01.002_bib186","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000227554","article-title":"Pentostatin (2\u2032-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group","volume":"53","author":"Monfardini","year":"1996","journal-title":"Oncology"},{"key":"10.1016\/j.blre.2005.01.002_bib187","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X05000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X05000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T02:37:10Z","timestamp":1682995030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X05000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":187,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0268960X05000032"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2005.01.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}